MVA 85A -Protocol 008

Full Title:

A Phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy volunteers with no evidence of infection with Mycobacterium tuberculosis

Study description:

The objective of the study is to test safety and immunogenicity of the vaccine MVA85A.

The study methodology is open label, with 24 healthy adults, and 12 healthy BCG-vaccinated adolescents vaccinated and monitored for a year.

The study timeline is between 2005 and 2008.

Principal Investigator: Greg Hussey Co-PI: Helen McShane

Partners: Oxford University, Wellcome Trust


Hawkridge J Infect Dis. 2008

Scriba Eur J Immunol. 2010